Extended adjuvant therapy with letrozole: reducing the risk of recurrence

Research output: Contribution to journalArticlepeer-review


Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement. Tamoxifen has been the standard therapy for reducing risk of recurrence, although more than 50% of relapses and deaths occur after completion of tamoxifen. Tamoxifen use is associated with an increased risk of serious side effects, and extended use beyond 5 years may have a negative impact on disease-free survival. Extended adjuvant letrozole therapy confers a significant benefit in relapse-free survival. The approval of letrozole for this indication in the USA and in many European countries introduces a new, safe and effective treatment for disease-free patients seeking to reduce their long-term risk of recurrence.
Original languageEnglish
Pages (from-to)849-59
Number of pages11
JournalExpert Review of Anticancer Therapy
Issue number6
Publication statusPublished - Jun 2006


  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Recurrence, Local
  • Nitriles
  • Tamoxifen
  • Triazoles


Dive into the research topics of 'Extended adjuvant therapy with letrozole: reducing the risk of recurrence'. Together they form a unique fingerprint.

Cite this